Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Christopher Flowers; Hervé Tilly; Franck Morschhauser; Laurie H. Sehn; Jonathan W. Friedberg; Marek Trněný; Jeff P. Sharman; Charles Herbaux; John M. Burke; Matthew Matasar; Shinya Rai; Koji Izutsu; Neha Mehta-Shah; Lucie Oberic; Adrien Chauchet; Wojciech Jurczak; Yuqin Song; Richard Greil; Larysa Mykhalska; Juan Miguel Bergua-Burgués; Matthew C. Cheung; Antonio Pinto; Ho-Jin Shin; Greg Hapgood; Eduardo Munhoz; Pau Abrisqueta; Jyh-Pyng Gau; Jamie Hirata; Yanwen Jiang; Mark Yan; Calvin Lee; Gilles Salles

doi:10.1016/S2152-2650(22)00699-1

Retour

Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Article de revue

Avec comité de lecture

Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Christopher Flowers, Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, …

Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S117-S117

10/2022

DOI: https://doi.org/10.1016/S2152-2650(22)00699-1

Indicateurs

1 Consultations de la notice

Détails

Titre: Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Créateurs - sans rôle: Christopher Flowers - The University of Texas MD Anderson Cancer Center, Houston, USA
Hervé Tilly - Centre Henri Becquerel
Franck Morschhauser - Université de Lille
Laurie H. Sehn - University of British Columbia
Jonathan W. Friedberg - Wilmot Cancer Institute, University of Rochester, Rochester, USA
Marek Trněný - Charles University
Jeff P. Sharman - Willamette Valley Cancer Institute/US Oncology, Eugene, USA
Charles Herbaux - CHU de Montpellier, Montpellier, France
John M. Burke - Rocky Mountain Cancer Centers/US Oncology, Aurora, USA
Matthew Matasar - Memorial Sloan Kettering Cancer Center, New York City/Montvale, USA
Shinya Rai - Kindai University
Koji Izutsu - National Cancer Center Hospital, Tokyo, Japan
Neha Mehta-Shah - Washinggton University in St. Louis, St. Louis, USA
Lucie Oberic - Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, France
Adrien Chauchet - CHRU Besançon, Besançon, France
Wojciech Jurczak - Maria Sklodowska – Curie National Research Institute of Oncology, Krakow, Poland
Yuqin Song - Peking University Cancer Hospital, Beijing, China
Richard Greil - Paracelsus Medical University
Larysa Mykhalska - Clinical Hospital Feofaniya, Kyiv, Ukraine
Juan Miguel Bergua-Burgués - Hospital San Pedro de Alcántara, Cáceres, Spain
Matthew C. Cheung - Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada
Antonio Pinto - Hematology-Oncology & Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione ‘G. Pascale', IRCCS, Naples, Italy
Ho-Jin Shin - Pusan National University Hospital
Greg Hapgood - Princess Alexandra Hospital, Brisbane, Australia
Eduardo Munhoz - Hospital Erasto Gaertner, Curitiba, Brazil
Pau Abrisqueta - Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Jyh-Pyng Gau - Taipei Veterans General Hospital, Taipei, Taiwan
Jamie Hirata - Genentech, Inc., South San Francisco, USA
Yanwen Jiang - Genentech
Mark Yan - Hoffmann-La Roche Ltd, Mississauga, Canada
Calvin Lee - Genentech, Inc., South San Francisco, USA
Gilles Salles - Memorial Sloan Kettering Cancer Center, New York City, USA
Détails de publication: Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S117-S117
Éditeur: Elsevier Inc
Identifiants: 99139787309311
Unité académique: Institut de Génétique Humaine - IGH
Langue: English
Type de ressource: Journal article